Nanopharm Ltd is a UK-based specialist contract research and development organization focused on orally inhaled and nasal drug products (OINDPs). Operating as part of Aptar Pharma’s services platform, the company supports pharmaceutical and biotech clients developing dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and nasal drug delivery systems.
Nanopharm’s capabilities span formulation development for powders and liquids, device–drug combination optimization, and comprehensive in vitro characterization, including emitted dose and aerodynamic particle size distribution. The company applies advanced modeling and analytical approaches to assess airway deposition, support in vitro–in vivo relationships, and build bioequivalence strategies for complex generics and innovator products. Its work includes performance testing, device selection and compatibility assessments, and regulatory support across the development lifecycle for respiratory and nasal therapies.
None yet. When a new project in the record names Nanopharm as owner, partner or investor, it shows here.
Aptar's nasal system aids LTR Pharma's SPONTAN® Phase II study, focusing on safety, tolerability, and pharmacokinetics for erectile dysfunction treatment.
The collaboration explores using Aptar's DPI platform for COVIRIX's antiviral delivery, targeting respiratory viruses with high local efficacy and minimal side effects.
